| Andrew R Haas, MD | |
|
3400 Spruce Street, Philadelphia, PA 19104-4206 | |
| (215) 662-3202 | |
| (215) 955-6003 |
| Full Name | Andrew R Haas |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 25 Years |
| Location | 3400 Spruce Street, Philadelphia, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083638035 | NPI | - | NPPES |
| 101498328 | Medicaid | PA | |
| 0092665 | Medicaid | NJ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0200X | Internal Medicine - Critical Care Medicine | MD422156 (Pennsylvania) | Secondary |
| 207RP1001X | Internal Medicine - Pulmonary Disease | MD422156 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital Of Univ Of Pennsylvania | Philadelphia, PA | Hospital |
| Penn Presbyterian Medical Center | Philadelphia, PA | Hospital |
| Chester County Hospital | West chester, PA | Hospital |
| Pennsylvania Hospital | Philadelphia, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of Penn - Medical Group | 6204730955 | 3031 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.
Most universities are encouraging vaccination, and many have mandated vaccination for all students. Given the availability of effective vaccines, there is a growing need to reevaluate the importance of university COVID-19 protocols.
Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.
The extraordinary results of an in utero stem cell treatment could lead to a new treatment for babies with brittle bones, as well as a range of other disabling conditions, according to a maternal-fetal medicine researcher, now based at The University of Queensland (UQ).
University of Massachusetts Amherst Professor Hang Xiao, Clydesdale Scholar of Food Science, has received a $1.5 million grant from the National Institutes of Health to study how substances produced in the gut from citrus compounds are involved in decreasing inflammation in the colon.
› Verified 7 days ago
| Entity Name | University Of Penn - Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003923707 PECOS PAC ID: 6204730955 Enrollment ID: O20141216000111 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.
Most universities are encouraging vaccination, and many have mandated vaccination for all students. Given the availability of effective vaccines, there is a growing need to reevaluate the importance of university COVID-19 protocols.
Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.
The extraordinary results of an in utero stem cell treatment could lead to a new treatment for babies with brittle bones, as well as a range of other disabling conditions, according to a maternal-fetal medicine researcher, now based at The University of Queensland (UQ).
University of Massachusetts Amherst Professor Hang Xiao, Clydesdale Scholar of Food Science, has received a $1.5 million grant from the National Institutes of Health to study how substances produced in the gut from citrus compounds are involved in decreasing inflammation in the colon.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Andrew R Haas, MD 3400 Spruce Street, 3 Ravdin Building, Suite F, Philadelphia, PA 19104-4206 Ph: (215) 662-3202 | Andrew R Haas, MD 3400 Spruce Street, Philadelphia, PA 19104-4206 Ph: (215) 662-3202 |
News Archive
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved a change to the prescribing information for Letairis (ambrisentan 5 mg and 10 mg tablets), the company's once-daily treatment to improve exercise ability and delay clinical worsening in pulmonary arterial hypertension (PAH, WHO Group 1) patients with predominantly WHO Functional Class II-III symptoms.
Most universities are encouraging vaccination, and many have mandated vaccination for all students. Given the availability of effective vaccines, there is a growing need to reevaluate the importance of university COVID-19 protocols.
Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.
The extraordinary results of an in utero stem cell treatment could lead to a new treatment for babies with brittle bones, as well as a range of other disabling conditions, according to a maternal-fetal medicine researcher, now based at The University of Queensland (UQ).
University of Massachusetts Amherst Professor Hang Xiao, Clydesdale Scholar of Food Science, has received a $1.5 million grant from the National Institutes of Health to study how substances produced in the gut from citrus compounds are involved in decreasing inflammation in the colon.
› Verified 7 days ago
Philippe Olivier Szapary, MD Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 3400 Civic Center Blvd, East Pavilion, 2nd Floor, Philadelphia, PA 19104 Phone: 215-615-4949 | |
Dr. Jamie L. Garfield, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-5864 Fax: 215-707-6867 | |
Maria Esther Escorcia De Leon, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3401 N Broad St, Philadelphia, PA 19140 Phone: 215-707-1622 Fax: 215-707-0943 | |
Cherag Daruwala, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 2301 E Allegheny Ave, Suite 190b, Philadelphia, PA 19134 Phone: 215-926-3120 Fax: 215-926-3123 | |
Dr. Robert Burke, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 51 N 39th St, Philadelphia, PA 19104 Phone: 215-662-9436 Fax: 215-243-3208 | |
Eva Hassan Alsheik, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 219 N Broad St, 5th Floor, Philadelphia, PA 19107 Phone: 215-762-6071 | |
Dr. Jason Thomas Ackrivo, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 3400 Spruce St, Philadelphia, PA 19104 Phone: 215-614-0871 |